{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T05:14:34Z","timestamp":1761714874310,"version":"build-2065373602"},"reference-count":36,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","primary-care-diabetes.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Primary Care Diabetes"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1016\/j.pcd.2012.06.001","type":"journal-article","created":{"date-parts":[[2012,6,30]],"date-time":"2012-06-30T18:01:49Z","timestamp":1341079309000},"page":"329-335","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Predictors for the initiation of a basal supported oral therapy (BOT) in type 2 diabetic patients under real-life conditions in Germany"],"prefix":"10.1016","volume":"6","author":[{"given":"Karel","family":"Kostev","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franz-Werner","family":"Dippel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pcd.2012.06.001_bib0005","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1001\/jama.281.21.2005","article-title":"Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group","volume":"281","author":"Turner","year":"1999","journal-title":"JAMA"},{"year":"2008","series-title":"Deutscher Gesundheitsbericht Diabetes 2009","author":"Deutsche Diabetes Union (Hrsg.)","key":"10.1016\/j.pcd.2012.06.001_bib0010"},{"key":"10.1016\/j.pcd.2012.06.001_bib0015","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.pcd.2012.06.001_bib0020","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.pcd.2012.06.001_bib0025","doi-asserted-by":"crossref","first-page":"421","DOI":"10.7326\/0003-4819-141-6-200409210-00007","article-title":"Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus","volume":"141","author":"Selvin","year":"2004","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.pcd.2012.06.001_bib0030","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","article-title":"Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study","volume":"321","author":"Stratton","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.pcd.2012.06.001_bib0035","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1055\/s-0029-1239559","article-title":"Medical antihyperglycaemic treatment of type 2 diabetes mellitus: update of the evidence-based guideline of the German Diabetes Association","volume":"117","author":"Matthaei","year":"2009","journal-title":"Experimental and Clinical Endocrinology and Diabetes"},{"key":"10.1016\/j.pcd.2012.06.001_bib0040","first-page":"861","article-title":"Kardiovaskul\u00e4re Risikofaktoren bei Typ-2-Diabetikern in Deutschland \u2013 ein Versorgungsparadox","volume":"104","author":"Berthold","year":"2007","journal-title":"Deutsches \u00c4rzteblatt"},{"key":"10.1016\/j.pcd.2012.06.001_bib0045","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1055\/s-2006-924927","article-title":"Quality of care and extent of complications in a population-based sample of patients with type 2 diabetes mellitus. The KORA Survey 2000","volume":"131","author":"Icks","year":"2006","journal-title":"Deutsche Medizinische Wochenschrift"},{"key":"10.1016\/j.pcd.2012.06.001_bib0050","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1177\/0145721708317869","article-title":"Measuring psychological insulin resistance: barriers to insulin use","volume":"34","author":"Larkin","year":"2008","journal-title":"Diabetes Educator"},{"key":"10.1016\/j.pcd.2012.06.001_bib0055","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.2337\/diacare.28.11.2673","article-title":"Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study","volume":"28","author":"Peyrot","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pcd.2012.06.001_bib0060","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.2337\/dc06-9912","article-title":"Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes","volume":"29","author":"Nathan","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pcd.2012.06.001_bib0065","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/S0140-6736(08)60485-7","article-title":"Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial","volume":"371","author":"Bretzel","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.pcd.2012.06.001_bib0070","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1056\/NEJMoa075392","article-title":"Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes","volume":"357","author":"Holman","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.pcd.2012.06.001_bib0075","doi-asserted-by":"crossref","first-page":"254","DOI":"10.2337\/diacare.28.2.254","article-title":"Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes","volume":"28","author":"Janka","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pcd.2012.06.001_bib0080","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.2337\/diacare.26.11.3080","article-title":"The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients","volume":"26","author":"Riddle","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pcd.2012.06.001_bib0085","first-page":"3","article-title":"Insulin glargin mit oralen Antidiabetika: Vorteilhafter Einstieg in die Insulintherapie. Diabetes","volume":"18","author":"Kress","year":"2009","journal-title":"Stoffwechsel und Herz"},{"key":"10.1016\/j.pcd.2012.06.001_bib0090","unstructured":"Fachinformation Lantus\u00ae \u2013 100 Einheiten\/ml Injektionsl\u00f6sung in einem Fertigpen, Optiset\u00ae, 2010."},{"key":"10.1016\/j.pcd.2012.06.001_bib0095","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/j.clinthera.2007.08.020","article-title":"Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus","volume":"29","author":"Mullins","year":"2007","journal-title":"Clinical Therapeutics"},{"key":"10.1016\/j.pcd.2012.06.001_bib0100","first-page":"120","article-title":"Lebensqualit\u00e4t und Behandlungszufriedenheit unter langwirksamen Analoginsulinen. Systhematischer Review","volume":"133","author":"Hagenmeyer","year":"2009","journal-title":"Deutsche Medizinische Wochenschrift"},{"key":"10.1016\/j.pcd.2012.06.001_bib0105","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1055\/s-0029-1222595","article-title":"Kosten f\u00fcr antihyperglyk\u00e4mische Arznei- und Verbrauchsmittel und Therapiezufriedenheit bei Typ-2-Diabetes. Ergebnisse der Versorgungsforschungsstudie LIVE-DE","volume":"134","author":"Hauner","year":"2009","journal-title":"Deutsche Medizinische Wochenschrift"},{"key":"10.1016\/j.pcd.2012.06.001_bib0110","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1046\/j.1464-5491.2002.00743.x","article-title":"Changes in treatment after the start of oral hypoglycaemic therapy in Type 2 diabetes: a population-based study","volume":"19","author":"Donnan","year":"2002","journal-title":"Diabetic Medicine"},{"key":"10.1016\/j.pcd.2012.06.001_bib0115","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2337\/diacare.9.2.129","article-title":"Secondary failure to treatment with oral antidiabetic agents in non-insulin-dependent diabetes","volume":"9","author":"Groop","year":"1986","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pcd.2012.06.001_bib0120","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1056\/NEJM199603213341207","article-title":"Seminars in Medicine of the Beth Israel Hospital, Boston. Non-insulin-dependent diabetes mellitus \u2013 a genetically programmed failure of the beta cell to compensate for insulin resistance","volume":"334","author":"Polonsky","year":"1996","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.pcd.2012.06.001_bib0125","first-page":"243","article-title":"Factors associated with switching from oral hypoglycaemic agents to insulin therapy","volume":"60","author":"Spoelstra","year":"2002","journal-title":"Netherlands Journal of Medicine"},{"key":"10.1016\/j.pcd.2012.06.001_bib0130","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0002-9343(89)80695-3","article-title":"Characteristics of non-insulin-dependent diabetic patients with secondary failure to oral antidiabetic therapy","volume":"87","author":"Groop","year":"1989","journal-title":"American Journal of Medicine"},{"key":"10.1016\/j.pcd.2012.06.001_bib0135","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.2337\/diacare.15.11.1658","article-title":"Methodological issues in diabetes research. Measuring adherence","volume":"15","author":"Johnson","year":"1992","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pcd.2012.06.001_bib0140","doi-asserted-by":"crossref","first-page":"617","DOI":"10.5414\/CPP47617","article-title":"Validity and representativeness of the \u201cDisease Analyzer\u201d patient database for use in pharmacoepidemiological and pharmacoeconomic studies","volume":"47","author":"Becher","year":"2009","journal-title":"International Journal of Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.pcd.2012.06.001_bib0145","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1046\/j.1524-4733.2003.00242.x","article-title":"A checklist for retrospective database studies\u2014report of the ISPOR Task Force on Retrospective Databases","volume":"6","author":"Motheral","year":"2003","journal-title":"Value in Health"},{"key":"10.1016\/j.pcd.2012.06.001_bib0150","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s00103-008-0643-1","article-title":"Health services research based on routine data generated by the SHI","volume":"51","author":"Swart","year":"2008","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"key":"10.1016\/j.pcd.2012.06.001_bib0155","first-page":"193","article-title":"Internationale Harmonisierung von Arzneimitteltechnologien: Vision und Wirklichkei","author":"Haas","year":"2008","journal-title":"Telemed Proceedings"},{"key":"10.1016\/j.pcd.2012.06.001_bib0160","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1503\/cmaj.080547","article-title":"Initiation of insulin therapy in elderly patients taking oral antidiabetes drugs","volume":"180","author":"Perez","year":"2009","journal-title":"CMAJ"},{"key":"10.1016\/j.pcd.2012.06.001_bib0165","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/archinte.166.20.2191","volume":"166","author":"Barzilay","year":"2006","journal-title":"Archives of Internal Medicine"},{"key":"10.1016\/j.pcd.2012.06.001_bib0170","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/pds.760","article-title":"Refill compliance in type 2 diabetes mellitus: a predictor of switching to insulin therapy?","volume":"12","author":"Spoelstra","year":"2003","journal-title":"Pharmacoepidemiology and Drug Safety"},{"issue":"Suppl. 1","key":"10.1016\/j.pcd.2012.06.001_bib0175","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.2337\/dc08-S012","article-title":"Standards of medical care in diabetes\u20142008","volume":"31","author":"American Diabetes Association","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pcd.2012.06.001_bib0180","first-page":"53","article-title":"Clinical Practice Guidelines Expert Committee: clinical practice guidelines for the prevention and management of diabetes in Canada","volume":"32","author":"Canadian Diabetes and Association","year":"2008","journal-title":"Canadian Journal of Diabetes"}],"container-title":["Primary Care Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1751991812000691?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1751991812000691?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T23:54:01Z","timestamp":1761695641000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1751991812000691"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["S1751991812000691"],"URL":"https:\/\/doi.org\/10.1016\/j.pcd.2012.06.001","relation":{},"ISSN":["1751-9918"],"issn-type":[{"type":"print","value":"1751-9918"}],"subject":[],"published":{"date-parts":[[2012,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictors for the initiation of a basal supported oral therapy (BOT) in type 2 diabetic patients under real-life conditions in Germany","name":"articletitle","label":"Article Title"},{"value":"Primary Care Diabetes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcd.2012.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Primary Care Diabetes Europe. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}